Functional Brands Amends CFO Appointment Disclosure, Reveals Related-Party Contract with New CFO's Firm
MEHA has more than doubled off its 52-week low of $0.057 on elevated volume (8.4× avg).
Summary
Functional Brands Inc. filed an amended 8-K to disclose a previously unannounced related-party services agreement with an entity owned by its newly appointed Chief Financial Officer.
Key Events · Corporate Governance and Compliance · MEHA
-
Related-Party Contract Disclosed
The company amended its prior 8-K to disclose a Services Agreement with Atlas Bookkeeping, LLC, an entity owned by the newly appointed CFO, David R. Wells. This agreement was not disclosed in the original filing regarding his appointment.
-
Significant Contract Value
Atlas Bookkeeping, LLC has been providing services since November 2025. The monthly fee was increased from $13,000 to $18,000 effective April 15, 2026, with total payments to date of approximately $89,833.
-
Governance Concerns Raised
The initial omission of this related-party transaction, coupled with the new CFO's ownership of the service provider, raises questions about corporate governance and potential conflicts of interest, particularly for a company facing significant financial and operational challenges.
-
CFO Appointment Context
This disclosure follows the appointment of David R. Wells as CFO, Principal Financial Officer, Principal Accounting Officer, and a Board member, effective May 18, 2026, succeeding Tariq Rahim who transitioned to a non-executive role.
Analysis · MEHA · Life Sciences
This amendment reveals a significant related-party transaction that was omitted from the original filing announcing the new CFO's appointment. The company's newly appointed CFO, David R. Wells, owns Atlas Bookkeeping, LLC, which has been providing financial and administrative services to Functional Brands since November 2025. The monthly fee for these services was recently increased to $18,000, totaling approximately $89,833 paid to date. This arrangement, representing a substantial annual cost relative to the company's small market capitalization, raises governance concerns, especially given the company's ongoing financial challenges, recent large acquisition, and efforts to avoid delisting.
At the time of this filing, MEHA was trading at $0.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.06 to $8.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.